Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055
NCT ID: NCT00973076
Last Updated: 2011-06-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
19 participants
INTERVENTIONAL
2009-08-31
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Tor Kinase Inhibitor in Advanced Tumors
NCT00731263
Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours
NCT01194193
AZD0530 Study 21 - Phase I Study in Patients With Solid Tumours
NCT00704366
Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies
NCT01353781
A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies
NCT03980821
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AZD8055
AZD8055 will be administered orally
AZD8055
Tablets, orally administered, twice daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AZD8055
Tablets, orally administered, twice daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Relatively good overall health other than cancer
Exclusion Criteria
* Poor liver or kidney function
* Serious concomitant illness
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca Pharmaceuticals
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ian Smith
Role: STUDY_DIRECTOR
AstraZeneca
Tomohide Tamura
Role: PRINCIPAL_INVESTIGATOR
National Cancer Center Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Tokyo, , Japan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Asahina H, Nokihara H, Yamamoto N, Yamada Y, Tamura Y, Honda K, Seki Y, Tanabe Y, Shimada H, Shi X, Tamura T. Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study. Invest New Drugs. 2013 Jun;31(3):677-84. doi: 10.1007/s10637-012-9860-4. Epub 2012 Jul 28.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D1600C00003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.